Origami Therapeutics, Inc.
YC W22San Diego, US · Founded 2015 · 4 employees · 1 known investors
Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.
Founders & leadership· Y Combinator alumni (W22)
Origami Therapeutics, Inc. was founded in 2015 by Beth Hoffman and Leslie Schulze.
Investors · 1
Competitors · 2
by search overlap
Companies competing with Origami Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $502.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Origami Therapeutics, Inc. do?
- Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.
- Who founded Origami Therapeutics, Inc.?
- Origami Therapeutics, Inc. was founded by Beth Hoffman, Leslie Schulze in 2015.
- Who are Origami Therapeutics, Inc.'s investors?
- Origami Therapeutics, Inc.'s investors include Y Combinator.
- Where is Origami Therapeutics, Inc. headquartered?
- Origami Therapeutics, Inc. is headquartered in San Diego, US.